These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20032550)

  • 1. Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV.
    Boehme RE; Cameron S
    Antivir Ther; 2009; 14(8):1195-208. PubMed ID: 20032550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complications of HIV infection in an ageing population: challenges in managing older patients on long-term combination antiretroviral therapy.
    Zhao H; Goetz MB
    J Antimicrob Chemother; 2011 Jun; 66(6):1210-4. PubMed ID: 21421583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral therapy: are we aware of adverse effects?
    Wig N
    J Assoc Physicians India; 2002 Sep; 50():1163-71. PubMed ID: 12516702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
    Vella S; Palmisano L
    J HIV Ther; 2003 May; 8(2):27-8. PubMed ID: 15587479
    [No Abstract]   [Full Text] [Related]  

  • 7. The metabolic puzzle during the evolution of HIV infection.
    Salas-Salvadó J; García-Lorda P
    Clin Nutr; 2001 Oct; 20(5):379-91. PubMed ID: 11534932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV infection and advanced age emerging epidemiological, clinical, and management issues.
    Manfredi R
    Ageing Res Rev; 2004 Jan; 3(1):31-54. PubMed ID: 15164725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
    Tin EE; Bowonwatanuwong C; Desakorn V; Wilairatana P; Krudsood S; Pitisuttithum P
    Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):362-9. PubMed ID: 15916042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications.
    Tarr PE; Telenti A
    Antivir Ther; 2007; 12(7):999-1013. PubMed ID: 18018758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV Infection and its therapies.
    Wohl DA
    Top HIV Med; 2004; 12(3):89-93. PubMed ID: 15310940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
    Fantoni M; Del Borgo C; Autore C; Barbaro G
    Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Care of the HIV-positive patient in the emergency department in the era of highly active antiretroviral therapy.
    Venkat A; Piontkowsky DM; Cooney RR; Srivastava AK; Suares GA; Heidelberger CP
    Ann Emerg Med; 2008 Sep; 52(3):274-85. PubMed ID: 18358567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular disease and toxicities related to HIV infection and its therapies.
    Zareba KM; Miller TL; Lipshultz SE
    Expert Opin Drug Saf; 2005 Nov; 4(6):1017-25. PubMed ID: 16255661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic complications of HIV-1 antiretroviral therapy: the lipodystrophy syndrome.
    Borderi M; Verucchi G; Tadolini M; Spinosa S; Fortunato L; Talò S; Chiodo F
    New Microbiol; 2001 Jul; 24(3):303-15. PubMed ID: 11497090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic complications of antiretroviral therapy.
    Sweet DE
    Top HIV Med; 2005; 13(2):70-4. PubMed ID: 16082057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.